Authors:
Kiran Pulidindi, Kunal Ahuja
Download free PDF
Prebiotics Market Size & Share 2026-2035
Report ID: GMI410
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Immediate Delivery Available
Download Free PDF
Prebiotics Market
Get a free sample of this report
Get a free sample of this report Prebiotics Market
Is your requirement urgent? Please give us your business email
for a speedy delivery!
Prebiotics Market Size
The global prebiotics market was valued at USD 7.6 billion in 2025, is estimated at USD 8.2 billion in 2026, and is projected to reach USD 15.9 billion by 2035, expanding at an approximately 7.7% CAGR from 2026 to 2035.
Prebiotics Market Key Takeaways
Market Leader: Cargill Inc. led with over 9.5% market share in 2025.
Leading Players: Top 5 players in this market include Cargill Inc., Beneo GmbH, Ingredion Inc., FrieslandCampina Ingredients, Tate & Lyle PLC, which collectively held a market share of 40.5% in 2025.
Market volume is projected to rise from 2,763.79 thousand tons in 2025 to 5,627.72 thousand tons by 2035, at an approximately 7.4% CAGR. Prebiotics are non-digestible substrates that are selectively used by host microorganisms and confer a health benefit, a definition that places demonstrated biological function, rather than fiber content alone, at the center of the category [1]Global Prebiotic Association, Revisiting the Concepts of Prebiotic and Prebiotic Effect, 2024, pmc.ncbi.nlm.nih.gov.
Demand is shifting from occasional digestive remedies toward routine food, beverage, and supplement formats that can support microbiome-related health positioning. In McKinsey's wellness research, approximately half of surveyed consumers in the U.S., UK, and Germany reported purchasing functional-nutrition products in the preceding year; the proportion was roughly two-thirds among Gen Z and millennial respondents, with gut health among the most sought benefits. U.S. digestive-drink dollar sales increased 34% in the 12 months ending October 2024, illustrating how prebiotic and probiotic positioning has moved into high-frequency beverage occasions rather than remaining limited to specialist nutrition channels.
Supply economics remain uneven across ingredient classes. Chicory-root inulin benefits from a developed cultivation and processing base, but its cost profile remains exposed to crop availability and energy-intensive extraction, purification, and drying operations. FOS, GOS, MOS, XOS, and resistant starches broaden the addressable application base, although emerging oligosaccharides generally require more specialized bioconversion, purification, or formulation capabilities. This combination of expanding demand occasions and differentiated production economics favors suppliers able to translate microbiome science into stable, scalable ingredients.
GMI Analyst View
Our analysis indicates that the category's expansion rests on a change in how prebiotics are purchased: they are increasingly selected as an enabling ingredient for products positioned around digestion, immunity, satiety, and healthy aging, rather than as a stand-alone fiber addition. That shift matters because it expands the number of formulations in which a prebiotic can create value, while also raising the evidentiary threshold for suppliers seeking to defend a premium.
The projected rise in both market value and volume through 2035 suggests that growth cannot depend solely on premium specialty formats. Established ingredients such as chicory-derived inulin provide scale and formulation familiarity, while newer oligosaccharides create higher-value opportunities where clinical substantiation, purity specifications, or infant-nutrition suitability matter more than bulk economics. The commercial advantage therefore lies in linking ingredient performance, regulatory support, and application development rather than competing on extraction capacity alone.
This coverage addresses the global prebiotics market across type, source, functionality, application, and regional demand. The base year is 2025, with estimates for 2026 and forecasts through 2035.
Key Drivers
Functional nutrition is becoming a repeat-purchase category
Prebiotic demand is increasingly tied to daily consumption occasions. Functional-nutrition purchasing is already substantial among younger consumers in major developed markets, and gut health ranks among the benefits that consumers actively seek. This favors formats such as fortified beverages, snacks, dairy products, and powdered supplements, where the ingredient can be incorporated into an established habit rather than requiring a new consumption ritual.
Retail evidence supports that transition. Digestive drinks have gained momentum in the United States, where prebiotic and probiotic ingredients are among the functional components associated with category growth. As brands move from broad "wellness" language toward more specific digestive, immunity, and metabolic positioning, ingredient suppliers with application support and substantiation can participate in higher-value formulations.
Broader food and beverage use is increasing formulation demand
Inulin and related fructans have commercial relevance beyond microbiome positioning because they can contribute fiber, texture, sweetness management, and fat replacement in one formulation. That multifunctionality lowers the formulation trade-off for food manufacturers seeking nutritional improvement without sacrificing sensory performance. It also makes prebiotics relevant to conventional packaged-food reformulation, not only to products explicitly sold as gut-health offerings.
Synbiotic development further increases the strategic value of prebiotics in foods and supplements. A Tate & Lyle-supported study published in 2024 evaluated a synbiotic containing PROMITOR® Soluble Corn Fibre and reported cardiometabolic protection in an animal model, demonstrating how a prebiotic can form part of a broader scientific platform rather than carrying a health proposition alone [2]Tate & Lyle PLC, Study Reveals Link Between Gut Microbes and Heart Disease, December 3, 2024, tateandlyle.com.
Biocatalysis and alternative feedstocks are improving the supply proposition
Enzymatic production routes offer a pathway to more precise oligosaccharide structures with lower process severity than conventional chemical synthesis. Research on enzyme-driven technologies has reported substantial gains in yield and productivity for selected oligosaccharide pathways, including continuous GOS and FOS processing configurations. For suppliers, these advances can improve consistency and reduce the technical barriers to commercializing ingredients whose performance depends on chain length, linkage profile, or purity.
Feedstock innovation is equally consequential. Research on FOS production found that replacing synthetic culture media with sugarcane molasses and corn steep liquor materially reduced medium costs, indicating that agricultural by-products may improve the economics of selected bioprocesses. Commercial adoption will still depend on purification requirements, food-safety qualification, and reliable feedstock supply, but the direction of travel favors producers able to integrate process technology with circular raw-material strategies.
Key Restraints
Production costs remain material for differentiated ingredients
Chicory-derived inulin has established supply chains, but raw chicory root and energy are major contributors to production cost, leaving processors exposed to seasonal agricultural conditions and utility-price volatility. The effect is more acute for emerging prebiotics, where lower production scale and demanding purification specifications can limit use to supplements, infant nutrition, and specialty foods.
XOS illustrates the constraint. Reported industrial selling prices vary widely by purity, ranging from USD 3,430 to USD 10,640 per metric ton, which restricts use in high-volume price-sensitive applications despite its functional potential. Technology improvements can reduce this burden over time, but they do not remove the need for investment in enzymes, reactors, downstream separation, and application validation.
Regulatory treatment limits the language available to brands
Regulatory frameworks distinguish between an ingredient's physiological potential and the health claims a manufacturer may communicate. In the European Union, "prebiotic" may be treated as an implied health claim, requiring a substantiated relationship between a defined constituent, a microbiota-mediated mechanism, and a measurable physiological benefit [3]Fardet A et al. / ILSI Europe, Prebiotics in Food and Dietary Supplements: A Roadmap to EU Health Claims, November 2024, pmc.ncbi.nlm.nih.gov. This makes clinical evidence and carefully constructed on-pack communication central commercial assets.
The U.S. does not maintain a dedicated legal definition for prebiotics, although FDA has recognized several non-digestible carbohydrates as dietary fiber. Product communication consequently depends on the applicable dietary-fiber and structure/function claim framework. Fragmentation is also pronounced across Latin America, where prebiotic, probiotic, and postbiotic rules differ among national authorities and harmonized requirements remain limited. Suppliers serving multiple regions must therefore build regulatory dossiers by jurisdiction rather than relying on a single global evidence package.
GMI Analyst View
Our assessment suggests that the principal constraint is not consumer interest in gut health, but the conversion of that interest into products with credible, permitted, and affordable claims. Regulatory restrictions raise the value of clinical substantiation because evidence can determine both the language available to a brand and the price premium an ingredient can retain. The same evidence burden also slows smaller suppliers that lack the resources to develop jurisdiction-specific claim dossiers.
Cost pressure creates a parallel split in the market. Mature fibers can address mainstream food reformulation, while higher-cost oligosaccharides are likely to concentrate first in infant nutrition, supplements, and science-led functional foods. Process innovation and by-product feedstocks can narrow that gap, but commercial scale will depend on whether suppliers can preserve ingredient consistency and regulatory acceptability while lowering cost. This places manufacturing technology and regulatory capability on the same competitive plane.
Prebiotics Market Segment Analysis
By Type
Inulin accounted for USD 2,720.39 million in 2025 and is projected to reach USD 5,075.46 million by 2035, at a 6.49% CAGR. Its scale reflects established chicory-root processing and its utility in fiber fortification, texture modification, and calorie-reduction strategies. Inulin's flexibility supports demand across mainstream food applications, even where a manufacturer does not use explicit microbiome language.
FOS is projected to increase from USD 2,031.64 million in 2025 to USD 4,180.36 million by 2035, at a 7.53% CAGR. Its lower sweetness contribution relative to sucrose and fermentability make it relevant to reduced-calorie foods, beverages, and infant-nutrition formulations [4]Costa MAS et al., Fructooligosaccharides: A Comprehensive Review, 2025, mdpi.com. GOS rises from USD 1,584.46 million to USD 3,580.94 million over the same period, at an 8.53% CAGR. Its role in infant formula remains particularly important: a 2025 trade analysis reported that 57% of global infant-formula launches contained GOS.
Other oligosaccharides, including MOS and XOS, expand at a 9.07% CAGR from USD 825.19 million in 2025 to USD 1,962.42 million in 2035. MOS has an established animal-nutrition case: a 2024 meta-analysis found improved broiler body-weight gain and feed conversion among MOS-supplemented birds versus unsupplemented controls [5]Lima EMR et al., Mannan Oligosaccharide as Alternative to Infeed Antibiotics: A Meta-Analysis, 2024, doi.org. Resistant starch and related ingredients comprise the fastest-growing type grouping, projected to grow at a 9.39% CAGR, supported by dietary-fiber recognition and weight-management-oriented product development.
By Source
Roots account for USD 3,690.31 million in 2025 and remain the largest source category, reaching USD 7,087.26 million by 2035. Chicory root's established position in inulin supply supports scale, but seasonal cultivation and energy requirements keep the category exposed to agricultural and processing-cost movements.
Grain-derived inputs rise from USD 2,233.17 million to USD 4,745.86 million, at a 7.88% CAGR, supported by starch and arabinoxylan-based production pathways. Vegetable sources expand at a 9.00% CAGR, while other sources grow at 9.52% CAGR. Enzymatic conversion of pectin and agricultural side streams offers a route to diversify raw-material supply, although performance at commercial scale will depend on feedstock consistency and downstream purification economics.
By Functionality
Digestive health remains the largest functionality segment, increasing from USD 2,878.68 million in 2025 to USD 5,217.03 million in 2035. Its relatively slower 6.18% CAGR indicates a mature core use case rather than declining importance. The segment retains its central role because selective fermentation, short-chain fatty-acid production, and changes in the composition or activity of gut microorganisms remain fundamental to the prebiotic concept.
Immunity enhancement grows more quickly, at a 9.20% CAGR, from USD 2,177.32 million to USD 5,238.36 million. This trajectory reflects the migration of microbiome science into broader systemic-health positioning. Weight management advances at 8.38% CAGR, while bone health rises from USD 697.88 million to USD 1,239.33 million, supported by the established relationship between certain fermentable fibers and mineral absorption.
By Application
Food and beverages lead application demand, expanding from USD 3,690.62 million in 2025 to USD 7,289.07 million by 2035. The segment benefits from the ability of inulin, FOS, and similar ingredients to serve nutritional and sensory functions in a single formulation. Dietary supplements are the fastest-growing application, rising from USD 2,452.46 million to USD 5,780.28 million at an 8.98% CAGR, because they can accommodate higher-purity ingredients and more targeted health positioning.
Animal feed reaches USD 2,190.53 million by 2035, from USD 1,144.62 million in 2025. MOS and FOS use in poultry and other livestock applications is supported by the need for non-antibiotic gut-health tools; research has identified MOS as a potential alternative to in-feed antibiotics in poultry production,. This demand stream is less dependent on consumer-facing wellness trends and is instead tied to animal-performance economics and antibiotic-reduction strategies.
GMI Analyst View
We estimate that segment growth will progressively favor ingredients and applications that solve a specific commercial problem, rather than ingredients sold only on general gut-health awareness. GOS benefits from its fit with infant nutrition and substantiated health positioning, while MOS gains from an animal-feed use case tied to performance and antibiotic-replacement pressures. Resistant starch and alternative oligosaccharides offer faster growth potential, but their ability to scale will depend on processing cost and the clarity of their application advantage.
The widening gap between dietary-supplement growth and food-and-beverage growth also points to a revenue-quality shift. Food applications provide scale, yet supplements can support more targeted positioning, higher purity requirements, and greater value per ton. Suppliers with portfolios spanning bulk fibers and clinically differentiated oligosaccharides are better positioned to serve both sides of the market: high-volume reformulation demand and premium science-led nutrition.
Prebiotics Market Regional Analysis
North America
North America is the largest market in 2025, valued at USD 2,649.4 million, and is projected to reach USD 4,797.6 million by 2035 at a 6.8% CAGR. The region's strength comes from developed supplement distribution, functional-food innovation, and a regulatory environment in which several non-digestible carbohydrates are recognized as dietary fiber. ADM's Fibersol® received approval from Australia's Therapeutic Goods Administration as an active ingredient for specified health-product categories in September 2025, illustrating how North American ingredient suppliers are extending regulatory footprints beyond their home market [6]ADM, ADM's Fibersol® Approved by Therapeutic Goods Administration, September 29, 2025, adm.com.
Europe
Europe rises from USD 2,077.4 million in 2025 to USD 3,889.1 million in 2035, at a 7.2% CAGR. The region combines a substantial chicory-root supply base with sophisticated food formulation capabilities, but health-claim restrictions limit how directly products can be positioned as prebiotic. Evidence requirements under the EU health-claims framework favor suppliers that can connect a characterized ingredient to a defined physiological outcome.
Asia Pacific
Asia Pacific is projected to be the fastest-growing region, increasing from USD 1,949.5 million in 2025 to USD 5,243.9 million in 2035 at an 11.6% CAGR. Infant nutrition, supplement adoption, and market-specific regulatory advances support this pace. BENEO received Thailand's first Thai FDA approval for an exclusive prebiotic claim for Orafti® Inulin in September 2025, demonstrating the commercial significance of claim access in the region [7]BENEO GmbH, BENEO Secures First-Ever Thai FDA Approval for Exclusive Prebiotic Claim, September 18, 2025, beneo.com. Tata Chemicals reported approximately 3,000 MT of FOS dispatches in FY2024-25, with capacity utilization increasing to 76%, and outlined plans to double prebiotic production capacity over five years.
Latin America
Latin America expands from USD 590.2 million in 2025 to USD 1,211.3 million in 2035, at an 8.3% CAGR. Brazil, Mexico, and Argentina operate under distinct regulatory systems, requiring suppliers to manage national claim rules rather than a unified regional pathway. This fragmentation creates a practical advantage for companies that can provide local regulatory documentation alongside product-development support.
Middle East & Africa
Middle East & Africa grows from USD 360.2 million in 2025 to USD 796.9 million in 2035, at a 9.2% CAGR. The market remains comparatively small, but premium functional-food and supplement demand in urban centers creates opportunities for specialized ingredients. Reliance on imported prebiotic materials can increase exposure to freight, currency, and distributor-margin effects, making cost-efficient formulations particularly important for wider consumer access.
GMI Analyst View
We expect Asia Pacific to exert the greatest influence on the market's incremental growth because its projected 11.6% CAGR combines expanding consumer demand with large infant-nutrition and supplement channels. The region is not a single regulatory market, however. The value of local approval pathways is illustrated by Thailand's exclusive prebiotic claim authorization for BENEO, while India's expanding FOS operations show the relevance of domestic production capacity,.
North America and Europe remain essential profit pools, but their growth logic differs. North America benefits from advanced functional-nutrition commercialization, whereas Europe's claim environment rewards technical evidence and disciplined communication. The resulting regional portfolio favors suppliers that can pair scale in developed markets with local regulatory execution in faster-growing markets, rather than relying on a uniform global product and claims strategy.
Prebiotics Market Share & Competitive Landscape
Competition is concentrated among ingredient suppliers that can combine raw-material access, processing technology, regulatory expertise, clinical substantiation, and application support. The market scope includes ADM, Cargill Inc., Kerry Group plc, Ingredion Inc., International Flavors & Fragrances Inc. (IFF), BENEO GmbH, Roquette Frères, Yakult Honsha Co., Ltd., Tate & Lyle PLC, FrieslandCampina Ingredients, Tata Chemicals, Fonterra Co-operative Group Limited, Solactis Group, Cosucra Groupe Warcoing SA, and Nexira.
ADM is advancing a broader biotics platform around Fibersol® and related gut-health solutions. Its September 2025 TGA approval broadened the potential regulated-health-product use of Fibersol® in Australia. BENEO remains a significant chicory-root supplier and has added regulatory and portfolio capability through its Thai claim approval and its partnership with WACKER to commercialize 2'-fucosyllactose for infant-formula applications,.
GOS suppliers are positioned to benefit from the durability of infant-nutrition demand and from the wider shift toward synbiotic products. FrieslandCampina Ingredients received 16 FSANZ health claims in April 2025 covering specified outcomes for its ingredient portfolio, strengthening the commercial value of evidence-backed GOS offerings [8]FrieslandCampina Ingredients, FrieslandCampina Ingredients Achieves 16 New FSANZ Health Claims, April 3, 2025, frieslandcampinaingredients.com. Roquette's NUTRIOSE® soluble fibers received NutraStrong™ Prebiotic Verified certification in November 2025, reinforcing third-party verification as a differentiator in a category where generic fiber claims are increasingly insufficient.
Portfolio consolidation may alter competitive positioning. Ingredion announced a recommended all-cash acquisition of Tate & Lyle in June 2026, a transaction that would combine specialty-ingredient platforms and Tate & Lyle's prebiotic-fiber capabilities [9]Ingredion Incorporated, Ingredion Announces Recommended All-Cash Acquisition of Tate & Lyle, June 8, 2026, ir.ingredionincorporated.com. Ingredion also acquired Benicaros, an upcycled prebiotic fiber derived from carrot pomace, during the same period, highlighting interest in fibers that combine clinical positioning with by-product utilization. Tata Chemicals provides a different competitive model: its reported FOS dispatches and capacity-utilization increase indicate the strategic importance of regional production assets in India.
Recent Industry Developments
June 2026 - Ingredion announces recommended acquisition of Tate & Lyle
Ingredion announced a recommended all-cash acquisition of Tate & Lyle in June 2026. The proposed transaction would combine the companies' specialty-ingredient portfolios, including Tate & Lyle's prebiotic-fiber assets.
June 2026 - Ingredion acquires Benicaros
Ingredion acquired Benicaros, an upcycled prebiotic fiber derived from carrot pomace, from NutriLeads. The acquisition adds a sustainability-positioned dietary-fiber ingredient to Ingredion's portfolio.
November 2025 - Roquette receives prebiotic verification for NUTRIOSE®
Roquette announced that NUTRIOSE® soluble fibers received NutraStrong™ Prebiotic Verified certification from SGS Nutrasource.
September 2025 - ADM receives TGA approval for Fibersol®
ADM announced that Fibersol® was approved by Australia's Therapeutic Goods Administration as an active ingredient for biologicals, listed medicines, and prescription medicines.
September 2025 - BENEO obtains Thai FDA claim approval
BENEO received Thai FDA approval for an exclusive prebiotic claim for Orafti® Inulin, marking a significant regulatory development for prebiotic ingredient communication in Thailand.
May 2025 - BENEO and WACKER launch 2'-FL partnership
BENEO and WACKER launched a strategic partnership to commercialize 2'-fucosyllactose, with WACKER supplying the human milk oligosaccharide and BENEO supporting market access for infant-formula applications.
April 2025 - FrieslandCampina Ingredients receives FSANZ health claims
FrieslandCampina Ingredients announced 16 FSANZ health claims associated with specified products and health outcomes, including gut health and mineral absorption.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Table of Contents
Chapter 1 Methodology & Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, By Type, 2022–2035 (USD Million) (000 Tons)
Chapter 6 Market Estimates and Forecast, By Source, 2022–2035 (USD Million) (000 Tons)
Chapter 7 Market Estimates and Forecast, By Functionality, 2022–2035 (USD Million) (000 Tons)
Chapter 8 Market Estimates and Forecast, By Application, 2022–2035 (USD Million) (000 Tons)
Chapter 9 Market Estimates and Forecast, By Region, 2022–2035 (USD Million) (000 Tons)
Chapter 10 Company Profiles
Don't see your key competitors?
The companies listed in this report are a curated selection - not the full competitive universe.
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled. The profiles section spotlights strategically significant players; it does not define the scope of our market sizing.
Your competitive landscape may also include
Free customization - up to 20% of report value
Need specific data? Request customization and get the insights tailored to your exact requirements.
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →